10 April 2017

Collagen-Based Spray Adhesive Shows Promising Data for Wound Care Applications

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, presented a poster at the Society for Biomaterials (SFB) Annual Meeting in Minneapolis, under the category "Active Wound Dressings for Advanced Wound Care", highlighting new data related to a wound healing project from their fibrillar collagen development programme.

The conference ran from April 5-8 and draws clinicians, researchers, and medical device manufactures from around the world to present innovative research, introduce new technologies, and encourage collaborations for the translation of academic research to clinical practice. At the meeting, scientists from the Company presented a poster titled ‘Evaluation of Fibroblast Behavior on a Collagen-Based Spray Adhesive' (#507), which expands on the Company's investigation into the potential for a fibrillar collagen-based spray that protects autologous cells during delivery and promotes cellular adhesion to a wound site.

The long-term potential of the research may address the limitations of current split or full-thickness autologous skin grafts, particularly in large wound sites. One of the primary disadvantages of these procedures is the lack and size of healthy donor sites that can be used; however, a much smaller amount of donor skin is required when autologous cells are harvested and expanded ex-vivo prior to being delivered to the wound.

Commenting on the presentation, Jamal Rushdy, CEO of Collagen Solutions said: "The expansion of this research project and the presentation of additional data in Minneapolis shows continued promise for the possible applications of our fibrillar collagen, and is part of our broader strategy to develop innovative finished devices. In particular, this novel mechanism for autologous cell delivery via a fibrillar collagen-based spray has the potential to address current shortcomings of products that serve the $3.8 Bn global regenerative wound healing market."

Additional meeting details can be accessed on the conference website and the poster can be viewed on the Company's website here.

About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information, visit www.collagensolutions.com



Collagen Solutions Plc Contact via Walbrook
Jamal Rushdy, Chief Executive Officer
Gill Black, Chief Financial Officer
Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox 
Tel: 0207 397 8900
Walbrook PR
Mike Wort
Anna Dunphy
Tel: 020 7933 8780 or collagen@walbrookpr.com
Mob: 07900 608 002
Mob: 07876 741 001